{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.7"}]}],"title":"Subject MM-82"},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.9"}]}],"title":"Subject MM-91"},{"categories":[{"measurements":[{"groupId":"OG000","value":"7"}]}],"title":"Subject MM-95"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.1"}]}],"title":"Subject MM-96"},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.8"}]}],"title":"Subject MM-98"},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.6"}]}],"title":"Subject MM-99"},{"categories":[{"measurements":[{"groupId":"OG000","value":"80"}]}],"title":"Subject MM-109"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.1"}]}],"title":"Subject MM-111"}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"}],"units":"Participants"}],"description":"Multiple myeloma cells are added to assay with dexamethasone. Cell viability and IC50 is determined. IC50 is the inhibitory concentration that kills 50% of cells. Results are reported in concentrations E-6.","groups":[{"description":"Patients undergo collection of blood and/or bone marrow samples for testing via in vitro chemosensitivity assay. Regardless of assay results, patients receive panobinostat PO on days 1, 3, 5, 15, 17, and 19, and carfilzomib IV and dexamethasone PO on days 1, 2, 8, 9, 15, and 16. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Chemo Assay and Treatment With Panobinostat, Carfilzomib, and Dexamethasone"}],"paramType":"NUMBER","populationDescription":"Results for subject MM-92 were not reported.","reportingStatus":"POSTED","timeFrame":"At baseline","title":"Multiple Myeloma Cells In-vitro Drug Sensitivity to Dexamethasone, by Subject","type":"PRIMARY","unitOfMeasure":"uM"}